The protective effects of rutaecarpine on acute pancreatitis

LU YAN¹, QING-FU LI¹, YAN-TING RONG¹, YONG-HENG CHEN², ZHAO-HONG HUANG¹, ZHI-ZHI WANG¹ and JIE PENG¹

¹Department of Gastroenterology; ²Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Received December 4, 2015; Accepted October 13, 2017

DOI: 10.3892/ol.2017.7659

Abstract. Acute pancreatitis (AP) is the acute inflammation of the pancreas. The morbidity of AP has increased in recent years. Certain patients eventually develop severe AP (SAP), which rapidly progresses to multiple organ dysfunction; the incidence of this occurring in patients with AP is 20-30%. To date, no specific drugs or methods exist to treat this disease. Rutaecarpine relaxes vascular smooth muscle by stimulating calcitonin gene-related peptide (CGRP) release via activation of vanilloid receptor subtype 1 (VR1). It has been demonstrated that rutaecarpine induces a therapeutic effect on SAP. The present study was conducted to characterize the molecular mechanisms underlying the protective effects of rutaecarpine against AP using a rat model of AP. Gross pathological changes of the pancreas, as well as the pancreatic tissue histopathological score, were assessed following treatment with rutaecarpine, capsazepine or a combination of the two. Serum amylase activity was detected using an automatic biochemistry analyzer. Changes in the serum concentrations of interleukin (IL)-6, tumor necrosis factor (TNF-α), IL-10 and CGRP were assessed by ELISA and radioimmuno assay. The results demonstrated that pre-treatment with rutaecarpine markedly decreased pancreatic inflammation and necrosis, reduced the volume of ascites, and significantly increased the plasma concentration of CGRP and the serum concentration of IL-10, an anti-inflammatory cytokine. However, serum concentrations of the inflammatory cytokines IL-6 and TNF-α were decreased. The effect of rutaecarpine treatment markedly improved with increases in the drug dose. Capsazepine, as a competitive vanilloid receptor antagonist, abolished these protective effects of rutaecarpine against AP. Therefore, the results of the present study indicate that rutaecarpine protects against AP in rats by upregulating endogenous CGRP release via activation VR1 of, to improving the microcirculation of the pancreatic tissue and regulate the expression of inflammatory factors.

Introduction

Acute pancreatitis (AP) is a severe disease that affects the abdomen and its incidence is increasing from 13 to 45/100,000 (1,2). In the majority of cases, AP is a mild and self-limiting disease; however, ~30% of patients will develop severe acute pancreatitis (SAP), which is characterized by severe attacks, including pancreatic necrosis, intestinal barrier dysfunction and bacterial translocation, leading to multiple organ dysfunction (5-20%) (3-5). Currently, the mechanisms involved in the pathogenesis of AP and associated pancreatic injury have not been fully elucidated. Among the various hypotheses used to explain the development of AP, microcirculatory disturbance and inflammatory mediation have attracted the most attention (6). Pancreatic microcirculatory disorders may be important pathogenic factors in determining acute pancreatitis (7) and it has been suggested that a number of factors are involved in the development of pancreatic microcirculatory disturbance (8). A number of pro-inflammatory cytokines may be released from damaged pancreatic tissue (9). These cytokines may cause multiple organ injury by instigating and aggravating microcirculatory disturbances (6). Current pharmaceutical therapies used to treat AP focuses on reducing pancreatic secretion and secondary injury (including fasting, protease inhibitors, antibiotics and fluid resuscitation). Due to unpredictable side effects and poor patient compliance, these therapies have a limited impact on the incidence and severity of AP (10). Therefore, a more in-depth understanding of the underlying molecular mechanisms, and the development of novel treatment strategies are required for AP.

Rutaecarpine (Fig. 1) is a quinazolinocarboline alkaloid isolated from Wu-Chu-Yu, the dried fruit of Evodia rutaecarpa Bentham (Rutaceae), a Chinese herbal drug (11). Rutaecarpine possesses a number of biological properties, including anti-hypertension, anti-thrombotic, anticancer and anti-inflammatory activities, particularly on relaxing vascular smooth muscle (12,13). Previous studies have revealed that the multiple pharmacological effects elicited by rutaecarpine are driven by the increase in endogenous calcitonin gene-related peptide.
peptide (CGRP) release following the activation of vanilloid receptor subtype 1 (VR1) (11,14). VR1, also known as the capsaicin receptor, is primarily expressed in sensory nerves. Primary sensory nerves sensitive to capsaicin are extensively distributed among different tissues and organs, and serve an important function in regulating peripheral vascular resistance (15). The activation of VR1 leads to the release of multiple neurotransmitters, including substance P (SP) and CGRP (16). Sensory nerves are important in limiting the development of AP and the stimulation of sensory nerves. Furthermore, the administration of CGRP may protect against pancreatic injury (17-19). Additionally, CGRP is a competitive VR antagonist, and therefore may be able to abolish the effects of VR (20).

It has been previously demonstrated that rutaecarpine has a therapeutic effect on SAP (21). However, to the best of our knowledge, the mechanism(s) responsible for the action of rutaecarpine in AP has not yet been reported. Previous studies performed in rats have indicated that the effects of rutaecarpine on gastroprotection and vasodilation may be due to the increase in endogenous CGRP release following VR1 activation (11,22). CGRP immunoreactivity has been detected in nerve fibers innervating the pancreas (23). Therefore, the present study investigated the protective effects of rutaecarpine on AP in rats and examined whether the functional mechanisms of rutaecarpine are associated with an increase in endogenous CGRP release following the activation of VR1.

Materials and methods

 Animals. A total of 100 male Sprague-Dawley (SD) rats (Laboratory Animal Center, Xiangya Hospital, Central South University, China), weighing 250±50 g, were used in the present study. All animals were housed in a controlled temperature environment (25˚C; 50% humidity) with a 12-hour day/night rhythm with free access to standard laboratory chow and water. All animals received humane care in compliance with the National Institutes of Health standards (Guide for the Care and Use of Laboratory Animals, revised 1996) (24). The present study was approved by the Ethics Committee of the Xiangya School of Medicine, Central South University (Changsha, China).

 Reagents. Rutaecarpine (purity, >98%) was purchased from Shanghai Yuan Ye Biotechnology Co., Ltd. (Shanghai, China). Capsazepine (a competitive VR antagonist) (purity, >98%) and 45% sodium taurocholate were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Dimethyl sulfoxide and ethanol were mixed at a ratio of 1:4 and used to dissolve rutaecarpine. A vehicle containing 8% ethanol, 2% dimethyl sulfoxide and 90% saline was used to dissolve capsazepine.

 Modeling and grouping of animals. SD rats were randomly divided into 10 different groups (all n=10). The groups included were as follows: i) Sham-operated group (Sham), AP was not induced during surgery; ii) AP group (AP), 5% sodium taurocholate solution (1.0 ml/kg) was injected into rats to induce AP during surgery; iii) Sham-operated + rutaecarpine (100 µg/kg) group (Sham+Rut), rats were injected with 100 µg/kg rutaecarpine into the sublingual vein 20 min prior to surgery; iv) AP + rutaecarpine (30 µg/kg) group (AP+Rut L), rats received an injection of 30 µg/kg rutaecarpine into the sublingual vein 20 min prior to surgery, in which AP was not induced; v) AP + rutaecarpine (100 µg/kg) group (AP+Rut M), rats were injected with 100 µg/kg rutaecarpine into the sublingual vein 20 min prior to surgery, in which AP was induced; vi) AP + rutaecarpine (300 µg/kg) group (AP+Rut H), rats were injected with 300 µg/kg rutaecarpine into the sublingual vein 20 min prior to surgery, in which AP was induced; vii) sham-operated + capsazepine group (Sham+Cap), animals were injected with 3 mg/kg capsazepine into the sublingual vein 30 min prior to surgery, in which AP was not induced; viii) AP + capsazepine group (AP+Cap), animals were injected with 3 mg/kg capsazepine into the sublingual vein 30 min prior to surgery; ix) AP + capsazepine + rutaecarpine (100 µg/kg) group (AP+Cap+Rut), mice were injected with 3 mg/kg capsazepine into the sublingual vein 30 min prior to surgery and were subsequently injected with 100 µg/kg rutaecarpine into the sublingual vein 20 min prior to surgery, in which AP was induced; and x) vehicle control group (AP+Sol), mice were injected with the vehicle [a mixture of dimethyl sulfoxide and ethanol (1:4) in a volume of 0.125 ml/kg] into the sublingual vein 20 min prior to surgery, in which AP was induced.

 SD rats were fasted for 12 h prior to surgery. Subsequently, rats were administered 3% pentobarbital sodium (40 mg/kg; Sigma-Aldrich; Merck KGaA) intraperitoneally to induce anesthesia. Following a conventional disinfection (first with 2.5% iodine infuion, followed by drying with 70% alcohol twice) and towel spreading, an incision (~1.5 cm) along the white line of abdomen was created. Freshly prepared 5% sodium taurocholate solution was used to induce AP by retrograde infusion through the cholangiopancreatic duct following laparotomy (25). Instead of 5% sodium taurocholate solution, an equivalent volume of normal saline solution was administered to the Sham group. The incision was closed with a continuous silk suture. All rats were sacrificed 24 h after surgery and arterial blood and pancreatic tissue were collected. The serum was collected following centrifugation (4°C, 1,500 x g for 5 min) and stored at -20°C. Pancreatic tissue was fixed in 4% phosphate-buffered formaldehyde at 4°C prior to histopathological examination.

 Detection of ascite volume. The abdomen was opened following euthanasia of the rats (all rats were sacrificed 24 h after surgery), ascites were removed from the abdominal cavity using a syringe and a measuring cylinder was used to measure the volume of the ascites.

 Histopathology. Formaldehyde-fixed pancreatic tissues obtained from the rats were embedded in paraffin, sectioned at 4 μm thick, and were dewaxed in xylene, rehydrated through decreasing concentrations of ethanol and then washed in PBS. Sections were stained with hematoxylin (4 min), washed with H₂O₂, and then 0.5% eosin (1 min) at room temperature. Two independent pathologists, who were blinded to this experiment, evaluated the sections under a light microscope. As outlined by the histopathological features scoring criteria (26),
the severity of pancreatitis was scored according to edema, vacuolization, necrosis and inflammation.

Measurement of serum amylase activity. Serum amylase activity was measured using a Hitachi 7170A full-automatic biochemical analyzer (Hitachi, Ltd., Tokyo, Japan) according to the manufacturer's protocol (α-Amy-DR; Autec Diagnostics, Bötzingen, Germany).

Cytokines assay. ELISA was performed to measure the serum concentrations of interleukin (IL)-6 (Rat IL-6 ELISA kit; cat. no. JER-04), IL-10 (Rat IL-10 ELISA kit; cat. no. JER-05) and tumor necrosis factor (TNF)-α (Rat TNF-α ELISA kit; cat. no. JER-06), according to the manufacturer's protocol (all products were purchased from Joyee Biotechnics Co., Ltd., Shanghai, China). Absorbance values were used to determine cytokine concentrations using a standard curve. All samples were tested three times.

Measurement of plasma CGRP concentration. Plasma was collected when rats were sacrificed 24 h after surgery by centrifugation at 1,000 x g for 30 min at 4°C. Subsequently, CGRP concentration in plasma was measured using a radioimmunoassay kit, according to the manufacturer's protocols.

Statistical analysis. All results are presented as the mean ± standard deviation and were analyzed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). Results were compared between all groups using one-way analysis of variance and least significant difference t tests were used to compare two different groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Pathological changes of the pancreas. To investigate the protective role of rutaecarpine in a rat model of AP, histopathological changes of the pancreas in rats from each group were assessed by evaluating H&E-stained tissue. Representative histological sections are presented in Fig. 2. There were no evident histopathological changes identified in the pancreas of mice from the Sham, Sham+Rut and Sham+Cap groups (Fig. 2A, C and G); however, the interlobular septum was slightly broadened in Sham+Rut group. There were varied degrees of pathological changes in the pancreatic acinar, including acute inflammation, necrosis, dilated intercellular spaces and interlobular septum in the other groups (Fig. 2B, D-F and H-J). Conspicuous hemorrhagic necrosis, pancreatic edema, interstitial leukocyte and erythrocyte infiltration, and acinar cell vacuolization were observed in the AP and AP+Sol groups (Fig. 2B and J). Compared with the AP group, the extent and severity of pancreatic injuries were markedly alleviated in the AP+Rut L, AP+Rut M and AP+Rut H groups (Fig. 2D-F and K). Rutaecarpine (30, 100 and 300 µg/kg) significantly decreased the severity of pathological changes in a dose-dependent manner (Fig. 2D-F and K). As presented in Fig. 2K, pancreatic histological scores were highest in the AP+Cap and AP+Cap+Rut groups; they were even significantly higher than in the AP group (P<0.05). Coagulative necrosis was observed in these two groups, which also exhibited widened interlobular septums and the disappearance of acinic structures (Fig. 2H and I).

Changes in the volume of ascites and serum amylase activity. In the Sham, Sham+Rut and Sham+Cap groups, ascite volume in the abdominal cavity of rats was low and barely detectable (Fig. 3) and serum amylase activity remained low in these 3 groups (Fig. 4). Ascite volume significantly increased in the AP and AP+Sol groups (P<0.05; Fig. 3). Furthermore, compared with the Sham groups, the AP groups exhibited markedly increased levels of serum amylase (P<0.05; Fig. 4). However, pre-treatment with 30, 100 and 300 µg/kg rutaecarpine significantly reduced the volume of ascites and serum amylase activity in a dose-dependent manner (P<0.05). Capsazepine, a competitive VR1 antagonist reversed these effects (Figs. 3 and 4).

Changes in inflammatory cytokines. Cytokines serve an important function in the systemic response in AP; therefore, changes in the levels of IL-10, IL-6 and TNF-α were assessed in the serum of the rats to identify the mechanism by which rutaecarpine protects against rutaecarpine in AP. Groups in which AP was induced by injection of 5% sodium taurocholate exhibited a marked increase of IL-6 and TNF-α serum concentrations (Fig. 5). IL-6 and TNF-α are two pro-inflammatory cytokines expressed in response to local damage to the pancreas. Pre-treatment with 30, 100 and 300 µg/kg rutaecarpine significantly reduced IL-6 and TNF-α levels compared with the AP group in a dose-dependent manner (P<0.05; Fig. 5). Furthermore, pre-treatment with rutaecarpine significantly increased serum concentrations of IL-10 (P<0.05; Fig. 6), an anti-inflammatory cytokine that may attenuate pancreatic damage (27). However, rats injected with capsazepine prior to surgery exhibited significantly higher IL-6 and TNF-α concentrations (P<0.05) and significantly lower serum IL-10 concentrations (P<0.05) compared with those treated with rutaecarpine. This indicates that rutaecarpine suppresses the inflammatory response in AP, an effect that is reversed by capsazepine.

CGRP concentration in plasma. Pre-treatment with 30, 100 or 300 µg/kg rutaecarpine significantly upregulated CGRP concentrations in a dose-dependent manner (P<0.05; Fig. 7). Contrastingly, treatment with capsazepine led to a significant
YAN et al: RUTAEARPINE PROTECTS AGAINST AP

3124
decrease in plasma CGRP levels even when rutaecarpine was administered (P<0.05; Fig. 7). Taken together, these results indicate that capsazepine may attenuate the effect of rutaecarpine on CGRP concentration.

Discussion

The morbidity of patients with acute pancreatitis has increased in recent years. However, the pharmacological therapies currently used to treat AP are limited. Therefore, a more in-depth understanding of the pathogenic mechanisms of AP and the identification of novel treatment strategies to treat it, are urgently required. Microcirculatory disorders serve an important function in the pathogenesis of AP, as they cause hypoxic damage in focal tissue and eventually induce edema formation and necrosis (28). A variety of pro-inflammatory cytokines are released by injured pancreas tissue (9). These inflammatory mediators are involved in the entire AP process,
triggering and aggravating the microcirculatory disorders, which leads to injuries in multiple organs (28).

Rutaecarpine is a vasodilator that modulates peripheral vascular resistance and may be associated with the upregulation of endogenous CGRP release via activation of VR1 (15,29). VR1 is almost exclusively distributed in the primary sensory neurons (30). Various vasodilator neuropeptides, including CGRP, are released by sensory afferent fibers. CGRP regulates regional organ blood flow and vascular tone, and is a potent vasodilator (31). The mammalian pancreas is richly innervated by a number of different nerve fibers and CGRP immunoreactivity has been observed in these nerve fibers (23). Previous studies have demonstrated that sensory nerves limit the development of AP and that stimulation of sensory nerves or administration of CGRP may protect against pancreatic injury (17-19). It has been demonstrated that rutaecarpine has a therapeutic effect on SAP (21). However, to the best of our knowledge, the mechanism of rutaecarpine action in AP has not yet been described. The results of the present study indicate that pre-treatment with rutaecarpine alleviates pancreatic inflammation and necrosis in a rat model of pancreatitis, reducing the volume of ascites and serum amylase activity, whilst significantly increasing CGRP plasma concentration.

The effect of rutaecarpine treatment increased as the drug dose increased; however, its protective effects were attenuated by capsazepine. These results indicated that the protective effect of rutaecarpine against AP is mediated by upregulating endogenous CGRP release via the activation of VR1.

Inflammatory mediators are key players in the systemic response to AP (9) and induce and aggravate microcirculatory disturbance throughout the body (28). Local damage of the pancreas is accompanied by the presence of leukocytes that release various pro-inflammatory cytokines, including TNF-α, IL-6 and IL-1β. The balance between pro- and anti-inflammatory mediators modulates the inflammatory response to AP (32). The presence of IL-10, which is a major anti-inflammatory mediator in AP, diminishes pancreatic damage (27). Therefore, further research into treatments that can modulate various inflammatory mediators may provide a novel method of treating AP. Previous studies determined the anti-inflammatory role of CGRP: CGRP reduces the expression of IL-6, TNF-α and IL-8 by inhibiting stimulation of nuclear factor-κB (33) but upregulates the anti-inflammatory mediator IL-10 (34). The present study confirmed that rutaecarpine increases serum concentrations of IL-10 but reduces IL-6 and TNF-α levels by stimulating the release of CGRP. This effect was dose-dependent and was abolished by capsazepine.

Figure 5. Serum concentrations of IL-6 and TNF-α. (A) Sham; (B) AP; (C) Sham+Rut (100 µg/kg); (D) AP+Rut L (30 µg/kg); (E) AP+Rut M (100 µg/kg); (F) AP+Rut H (300 µg/kg); (G) Sham+Cap; (H) AP+Cap; (I) AP+Cap+Rut (100 µg/kg); (J) AP+Sol. Results are presented as the mean ± standard deviation. (n=10). *P<0.05 vs. (B), (D-F) and (H-J); †P<0.05 vs. (B); ‡P<0.05. IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; AP, acute pancreatitis; Rut, rutaecarpine; Cap, capsazepine.

Figure 6. Serum concentration of IL-10. (A) Sham; (B) AP; (C) Sham+Rut (100 µg/kg); (D) AP+Rut L (30 µg/kg); (E) AP+Rut M (100 µg/kg); (F) AP+Rut H (300 µg/kg); (G) Sham+Cap; (H) AP+Cap; (I) AP+Cap+Rut (100 µg/kg); (J) AP+Sol. Results are presented as the mean ± standard deviation. (n=10). *P<0.05 vs. (B); †P<0.05 vs. (E); ‡P<0.05. IL-10, interleukin-10; AP, acute pancreatitis; Rut, rutaecarpine; Cap, capsazepine.

Figure 7. Plasma CGRP concentrations. (A) Sham; (B) AP; (C) Sham+Rut (100 µg/kg); (D) AP+Rut L (30 µg/kg); (E) AP+Rut M (100 µg/kg); (F) AP+Rut H (300 µg/kg); (G) Sham+Cap; (H) AP+Cap; (I) AP+Cap+Rut (100 µg/kg); (J) AP+Sol. †P<0.05 vs. (E); ‡P<0.05. CGRP, calcitonin gene-related peptide; AP, acute pancreatitis; Rut, rutaecarpine; Cap, capsazepine.
Notably, although the rats in the AP group had not been treated with rutaecarpine prior to surgery, serum IL-10 concentrations increased slightly. This may be due to the protective effect against acute inflammation exhibited by living organisms.

In conclusion, the results of the present study indicate that rutaecarpine protects against injuries caused by AP in rats and that these effects are mediated by the release of CGRP via activation of VR1. Rutaecarpine induces an anti-inflammatory response in the treatment of AP. The results of the present study provide novel insights into the pharmacological therapy of AP.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant no. 81670589), the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry [grant no. (2015) 311] and the Project from Science and Technology Department, Hunan, China (grant no. 2015SF2020-3).

References